Latest News
Beverly, Massachusetts, USA. 19 September 2023. Seroba’s portfolio company, Quanta Dialysis Technologies®, a medical technology company committed to making kidney care more accessible, today announced that it has submitted a 510(k) premarket notification to the U.S. […]
Beverly, Massachusetts, U.S.A. 17 August 2023. Seroba’s portfolio company, Quanta Dialysis Technologies®, today announced that it has completed enrollment of its Home Run study for at-home hemodialysis. The Home Run study is a prospective, multi-center, open-label […]
Munich, Germany. 2 August 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, has announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer. Dr. Zamiri brings […]
Beverly, Mass., USA. 3 August, 2023. Quanta Dialysis System becomes first-in-class to perform three standard-of-care dialysis modalities in one device. Quanta Dialysis Technologies®, a medical technology company committed to making kidney care more accessible, today announced […]
Galway, Ireland and Oceanside, CA, USA. 28 July, 2023. Seroba’s portfolio company, Palliare, a leading developer of advanced insufflation technologies, has received EU CE Mark certification under the new EU Medical Devices Regulation (MDR) for its […]
Galway, Ireland. 9 June, 2023. Seroba portfolio company, Perfuze, a medical device company developing next-generation ”super-bore” catheter technology to treat acute ischemic stroke, is pleased to announce the appointment of Hooman Hakami as the new Chair […]
Paris, France. 31 May 2023. Seroba portfolio company, Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announces the positive 12-month results from […]
Lisle, Illinois, USA. 22 May 2023. Seroba’s portfolio company, Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced positive 12-month data from the SIRONA 2 […]
Munich, Germany. 17 April 2023. Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, today announced the completion of a €72 million Series A financing. The round was led […]
Lisle, Illinois, USA. 4 April 2023. Seroba’s portfolio company, Endotronix Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced its PROACTIVE-HF pivotal study successfully completed enrolment. […]